Neptune Signs John Elway, NFL Hall-of-Famer, as Official Brand Ambassador
2012年3月27日 - 9:00PM
Neptune Technologies & Bioressources (Nasdaq:NEPT) (TSX:NTB) is
very excited to announce that the company has entered into a
multi-year partnership with former NFL (National Football League)
Super Bowl Champion and Hall-of Fame quarterback, John Elway.
"I started feeling better soon after taking Neptune Krill Oil
(NKO®) on a daily basis. The health benefits were so significant,
that I wanted to be a part of their success in the Omega-3 market
worldwide," said John Elway. "There is no doubt in my mind that
NKO® improves cholesterol levels, alleviates joint pain, reduces
inflammation and helps with neurological conditions. Furthermore,
Omega-3's are rapidly showing promises proving to be beneficial for
those who have experienced concussions,'' he added.
John Elway's Testimonial Video - Just Krillin with NKO
"In his amazing 16 year career, which included two Super Bowl
Championships, a Super Bowl MVP, an NFL MVP award, and nine NFL Pro
Bowls, John Elway is easily one of the most recognizable and
successful athletes of all time," said André Godin, CFO.
John Elway retired in 1999 and statistically was the second most
prolific passer in NFL history. He is currently Executive Vice
President of Football Operations for the Denver Broncos in addition
to being part owner of four successful Elway's Restaurants and the
same number of automobile dealerships bearing his name.
''This is an exceptional day for our company and we could not be
more pleased to partner with one of the best professional football
players to ever play the game," said Henri Harland, CEO and
President. ''Neptune strives to be the best at every level to
ensure that we generate the highest level of value creation for our
shareholders. The addition of John Elway to our team is consistent
with that philosophy,'' he added.
About Neptune Technologies & Bioressources
Inc.
Neptune is an industry-recognized leader in the innovation,
production and formulation of science-based and clinically proven
novel phospholipid products for the nutraceutical and
pharmaceutical markets. The Company focuses on growing consumer
health markets including cardiovascular, inflammatory and
neurological diseases driven by consumers taking a more proactive
approach to managing health and preventing disease. The Company
sponsors clinical trials aimed to demonstrate its product health
benefits and to obtain regulatory approval for label health claims.
Neptune is continuously expanding its intellectual property
portfolio as well as clinical studies and regulatory approvals.
Neptune's products are marketed and distributed in over 30
countries worldwide.
About Acasti Pharma Inc.
Acasti Pharma (TSX-V:APO) is developing a product portfolio of
proprietary novel long-chain omega-3 phospholipids. Phospholipids
are the major component of cell membranes and are essential for all
vital cell processes. They are one of the principal constituents of
High Density Lipoprotein (good cholesterol) and, as such, play an
important role in modulating cholesterol efflux. Acasti Pharma's
proprietary novel phospholipids carry and functionalize the
polyunsaturated omega-3 fatty acids EPA and DHA, which have been
shown to have substantial health benefits and which are stabilized
by astaxanthin, a potent antioxidant. Acasti Pharma is focusing
initially on treatments for chronic cardiovascular and
cardiometabolic conditions within the over-the-counter, medical
food and prescription drug markets.
About NeuroBioPharm Inc.
NeuroBioPharm is pursuing pharmaceutical neurological
applications, and a clinical study for a medical food product with
a multinational partner is already initiated. The development of a
prescription drug candidate is currently in progress. Advanced
clinical development and commercialization is planned to be carried
out with multinational partners.
"Neither Nasdaq nor the TSX nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX) accepts responsibility for the adequacy or accuracy of this
release."
Statements in this press release that are not statements of
historical or current fact constitute "forward-looking
statements" within the meaning of the U.S. Private Securities
Litigation Reform Act of 1995 and Canadian securities laws. Such
forward-looking statements involve known and unknown risks,
uncertainties, and other unknown factors that could cause the
actual results of the Company to be materially different from
historical results or from any future results expressed or implied
by such forward-looking statements. In addition to statements which
explicitly describe such risks and uncertainties, readers are
urged to consider statements labeled with the terms "believes,"
"belief," "expects," "intends," "anticipates," "will," or
"plans" to be uncertain and forward-looking. The forward-looking
statements contained herein are also subject generally to other
risks and uncertainties that are described from time to time in the
Company's reports filed with the Securities and Exchange Commission
and the Canadian securities commissions.
CONTACT: Neptune Contact:
Neptune Technologies & Bioressources Inc.
Andre Godin, CFO
+1.450.687.2262
a.godin@neptunebiotech.com
www.neptunebiotech.com
Howard Group Contact:
Dave Burwell
(888) 221-0915
dave@howardgroupinc.com
www.howardgroupinc.com
Neptune Wellness Solutions (NASDAQ:NEPT)
過去 株価チャート
から 6 2024 まで 7 2024
Neptune Wellness Solutions (NASDAQ:NEPT)
過去 株価チャート
から 7 2023 まで 7 2024